Cargando…

Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients

Background and objectives Microalbuminuria is an early sign of diabetic nephropathy (DN). However, pathological abnormalities occur before the onset of microalbuminuria. Renal impairment progresses in about 50% of cases in type 2 diabetes mellitus (T2DM) without significant albuminuria. Diabetes mel...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonkar, Satyendra K, Gupta, Akash, Sonkar, Gyanendra K, Usman, Kauser, Bhosale, Vivek, Kumar, Satish, Sharma, Sharad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085351/
https://www.ncbi.nlm.nih.gov/pubmed/37051007
http://dx.doi.org/10.7759/cureus.36011
_version_ 1785021921289568256
author Sonkar, Satyendra K
Gupta, Akash
Sonkar, Gyanendra K
Usman, Kauser
Bhosale, Vivek
Kumar, Satish
Sharma, Sharad
author_facet Sonkar, Satyendra K
Gupta, Akash
Sonkar, Gyanendra K
Usman, Kauser
Bhosale, Vivek
Kumar, Satish
Sharma, Sharad
author_sort Sonkar, Satyendra K
collection PubMed
description Background and objectives Microalbuminuria is an early sign of diabetic nephropathy (DN). However, pathological abnormalities occur before the onset of microalbuminuria. Renal impairment progresses in about 50% of cases in type 2 diabetes mellitus (T2DM) without significant albuminuria. Diabetes mellitus (DM) is linked with obesity, metabolic syndrome, and lifestyle changes, where adipokines play an important role. Zinc alpha 2 glycoprotein (ZAGP) is an adipokine, and in this study, it was assessed as a potential biomarker for early DN as well as its progression. Materials and methods This study was a cross-sectional case-control study conducted at a tertiary hospital in northern India. T2DM patients aged 18-65 years old were included in the study and were divided into four groups based on their albuminuria level. This study included 160 participants, with 40 participants in each group. Group I included healthy volunteers, while Groups II, III, and IV were normoalbuminuric, microalbuminuric, and macroalbuminuric diabetic patients, respectively. The groups were evaluated for demographic variables, biochemical parameters, urine albumin-creatinine ratio (UACR), and serum ZAGP. Data between the groups were compared statistically. Results This study included 160 participants, with 40 participants in each group. There was a significant difference between the groups based on the serum ZAGP (p<0.001). Serum ZAGP was significantly negatively correlated with serum creatinine, glycosylated hemoglobin (HbA1c), serum cholesterol, serum triglyceride, low-density lipoprotein (LDL) cholesterol, and UACR. ZAGP was positively correlated with the estimated glomerular filtration rate (eGFR). Conclusion The present study showed that ZAGP was an early biomarker of diabetic nephropathy, and its value decreased as DN progressed. It also suggested that ZAGP, an adipokine, has an anti-inflammatory mechanism of action and its depletion worsens the disease.
format Online
Article
Text
id pubmed-10085351
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-100853512023-04-11 Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients Sonkar, Satyendra K Gupta, Akash Sonkar, Gyanendra K Usman, Kauser Bhosale, Vivek Kumar, Satish Sharma, Sharad Cureus Endocrinology/Diabetes/Metabolism Background and objectives Microalbuminuria is an early sign of diabetic nephropathy (DN). However, pathological abnormalities occur before the onset of microalbuminuria. Renal impairment progresses in about 50% of cases in type 2 diabetes mellitus (T2DM) without significant albuminuria. Diabetes mellitus (DM) is linked with obesity, metabolic syndrome, and lifestyle changes, where adipokines play an important role. Zinc alpha 2 glycoprotein (ZAGP) is an adipokine, and in this study, it was assessed as a potential biomarker for early DN as well as its progression. Materials and methods This study was a cross-sectional case-control study conducted at a tertiary hospital in northern India. T2DM patients aged 18-65 years old were included in the study and were divided into four groups based on their albuminuria level. This study included 160 participants, with 40 participants in each group. Group I included healthy volunteers, while Groups II, III, and IV were normoalbuminuric, microalbuminuric, and macroalbuminuric diabetic patients, respectively. The groups were evaluated for demographic variables, biochemical parameters, urine albumin-creatinine ratio (UACR), and serum ZAGP. Data between the groups were compared statistically. Results This study included 160 participants, with 40 participants in each group. There was a significant difference between the groups based on the serum ZAGP (p<0.001). Serum ZAGP was significantly negatively correlated with serum creatinine, glycosylated hemoglobin (HbA1c), serum cholesterol, serum triglyceride, low-density lipoprotein (LDL) cholesterol, and UACR. ZAGP was positively correlated with the estimated glomerular filtration rate (eGFR). Conclusion The present study showed that ZAGP was an early biomarker of diabetic nephropathy, and its value decreased as DN progressed. It also suggested that ZAGP, an adipokine, has an anti-inflammatory mechanism of action and its depletion worsens the disease. Cureus 2023-03-11 /pmc/articles/PMC10085351/ /pubmed/37051007 http://dx.doi.org/10.7759/cureus.36011 Text en Copyright © 2023, Sonkar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
Sonkar, Satyendra K
Gupta, Akash
Sonkar, Gyanendra K
Usman, Kauser
Bhosale, Vivek
Kumar, Satish
Sharma, Sharad
Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title_full Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title_fullStr Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title_full_unstemmed Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title_short Zinc Alpha 2 Glycoprotein as an Early Biomarker of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
title_sort zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in type 2 diabetes mellitus patients
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085351/
https://www.ncbi.nlm.nih.gov/pubmed/37051007
http://dx.doi.org/10.7759/cureus.36011
work_keys_str_mv AT sonkarsatyendrak zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT guptaakash zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT sonkargyanendrak zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT usmankauser zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT bhosalevivek zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT kumarsatish zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients
AT sharmasharad zincalpha2glycoproteinasanearlybiomarkerofdiabeticnephropathyintype2diabetesmellituspatients